Takeda Pharmaceutical Company (TAKN) Financial Statements
Takeda Pharmaceutical Company Financial Overview
Takeda Pharmaceutical Company's market cap is currently $1.27T. The company's EPS TTM is $122.21; its P/E ratio is 27.16; and it has a dividend yield of 3.06%. Takeda Pharmaceutical Company is estimated to report earnings on January 28, 2027, and the estimated EPS forecast is $5.30. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 4.78T | $ 4.58T | $ 4.26T | $ 4.03T | $ 3.57T |
| Gross Profit | $ 2.44T | $ 3.00T | $ 2.83T | $ 2.78T | $ 2.46T |
| Operating Income | $ 573.04B | $ 342.59B | $ 214.07B | $ 490.50B | $ 460.84B |
| EBITDA | $ 1.38T | $ 1.21T | $ 1.23T | $ 1.28T | $ 1.18T |
| Net Income | $ 203.33B | $ 107.93B | $ 144.07B | $ 317.02B | $ 230.06B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 597.63B | $ 405.59B | $ 472.89B | $ 553.70B | $ 875.00B |
| Total Assets | $ 15.52T | $ 14.25T | $ 15.11T | $ 13.96T | $ 13.18T |
| Total Debt | $ 4.90T | $ 4.52T | $ 4.84T | $ 4.38T | $ 4.35T |
| Net Debt | $ 4.31T | $ 4.13T | $ 4.39T | $ 3.85T | $ 3.50T |
| Total Liabilities | $ 7.71T | $ 7.31T | $ 7.83T | $ 7.60T | $ 7.49T |
| Stockholders' Equity | $ 7.81T | $ 6.94T | $ 7.27T | $ 6.35T | $ 5.68T |
| Cash Flow | |||||
| Free Cash Flow | $ 626.77B | $ 677.56B | $ 235.61B | $ 343.47B | $ 937.07B |
| Operating Cash Flow | $ 1.04T | $ 1.06T | $ 716.34B | $ 977.16B | $ 1.12T |
| Investing Cash Flow | $ -369.14B | $ -367.06B | $ -463.86B | $ -607.10B | $ -198.13B |
| Financing Cash Flow | $ -496.82B | $ -751.42B | $ -354.42B | $ -709.15B | $ -1.07T |
Currency in JPY